

The Risk-Screening Converter

Nicholas J Wald^[1], Stephen W Duffy^[2], Allan Hackshaw^[3]

¹Institute of Health Informatics, University College London, London, UK

²Wolfson Institute of Population Health, Queen Mary University of London, London, UK

³Cancer Institute, University College London, London, UK

Despite being documented it is not widely recognized that important causal risk factors of potential significance in the primary prevention of disease usually make poor screening tests.¹ This arises because the quantitative association between causal risk factors and disease is usually too small for the risk factor to be a useful screening test. Two examples are the measurement of serum cholesterol as a screening test for heart attacks¹ and blood pressure measurement as a screening test for stroke.² While these risk factors are the drivers of heart attacks and strokes throughout the world, when considered as screening tests, they typically have detection rates (sensitivities) for a 5% false positive rate (DR₅) of no more than 15% to 20%. Even non-causal risk factors have been invoked as screening tests when their screening performance is poor, for example, coronary calcification as a possible test for coronary heart disease.³ There is a numerical relationship between measures widely used in investigating causal risk factors such as relative risk or odds ratios and measures of screening performance such as the DR₅. A web-based Risk-Screening Converter is available on the Medical Screening Society website (<https://www.medicalscreeningsociety.com/rsc.asp>). The Risk-Screening Converter converts measures identified as risk factors in epidemiological studies which have a Gaussian distribution into measures of screening performance of potential tests and vice versa. The Converter can be used to determine whether measures such as the odds ratio across the highest and lowest quintile groups of a risk factor are large enough to be considered as a screening test.

For example, the Risk-Screening Converter can be used to show that cholesterol is not a good screening test for ischaemic heart disease. In a study of the concentration of total cholesterol in men with a future ischaemic heart disease event⁴ the odds ratio between the

highest and lowest quintile groups of the distribution of serum total cholesterol was approximately 3.3, similar to the results from other studies.^{5,6} When this odds ratio is entered into the Risk-Screening Converter (see [Figure 1](#)) an estimated DR₅ of 11.2% is obtained showing that serum cholesterol measurement in adults is not a good screening test for ischaemic heart disease despite it being widely used for this purpose.

The Converter has been used in a study to assess the incremental value of polygenic risk scores (PRS) over traditional risk factor scores in the prediction of coronary heart disease events.⁷ The study used the results from five cohorts. The cohort with the most discriminatory PRS⁸ reported an odds ratio of 4.51 between the highest and lowest quintile groups of the distribution of PRS. The Converter was used in the study⁷ to show that this odds ratio corresponds to a false positive rate of 77.1% at a 90% detection rate (FPR₉₀), which is equivalent to a DR₅ of 13.5%. The Converter shows that adding a PRS to traditional risk scores adds only a few percentage points to the DR₅.

The Risk-Screening Converter may be helpful in distinguishing genuinely worthwhile screening tests from tests of little or no value.

Declaration of conflicting interests


The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.



References

1. Wald NJ, Hackshaw AK, Frost CD. When can a risk factor be used as a worthwhile screening test? *Br Med J* 1999; 319: 1562–1565.
2. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. *Br Med J* 2003; 326: 1419.
3. Wald NJ, Morris JK. Assessing risk factors as potential screening tests: A simple assessment tool. *Arch Intern Med* 2011; 171: 286–291.
4. Pocock SJ, Shaper AG, Phillips AN. Concentrations of high density lipoprotein cholesterol, triglycerides, and total cholesterol in ischaemic heart disease. *Br Med J* 1989; 298: 998–1002.
5. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease overall findings and differences by age for 316099 white men. *Arch Intern Med* 1992; 152: 56–64.
6. Law MR, Wald NJ, Wu Tet al. et al. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: Data from the BUPA study. *Br Med J* 1994; 308: 363–366.
7. Groenendyk JW, Greenland P, Khan SS. Incremental value of polygenic risk scores in primary prevention of coronary heart disease: A review. *JAMA Intern Med* 2022; 182: 1082–1088.
8. Abraham G, Havulinna AS, Bhalala OGet al. Genomic prediction of coronary heart disease. *Eur Heart J* 2016; 37: 3267–3278.



Overlapping affected and unaffected distributions of a test variable

Shaded areas show the proportions of the affected and unaffected distributions above the cut-off level (detection rate and false positive rate)



Odds ratio of 3.3 corresponds to a detection rate of 11.2% for a fixed 5% false positive rate ($DR_5 = 11.2\%$) when the lowest and highest proportions of the unaffected distribution are both 20%. The standard deviations of affected and unaffected distributions are the same.

Figure 1. A screenshot from the Risk-Screening Converter illustrating the screening performance of a screening test for future ischaemic heart disease events using total cholesterol measurements. The figure shows that the odds ratio of having future ischaemic heart disease events between the highest and lowest quintile groups of a total cholesterol level of 3.3 converts to a DR_5 of 11.2%.